These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 11768292)

  • 1. Ways to fit a PK model with some data below the quantification limit.
    Beal SL
    J Pharmacokinet Pharmacodyn; 2001 Oct; 28(5):481-504. PubMed ID: 11768292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
    Yang S; Roger J
    Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Likelihood based approaches to handling data below the quantification limit using NONMEM VI.
    Ahn JE; Karlsson MO; Dunne A; Ludden TM
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):401-21. PubMed ID: 18686017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Handling data below the limit of quantification in mixed effect models.
    Bergstrand M; Karlsson MO
    AAPS J; 2009 Jun; 11(2):371-80. PubMed ID: 19452283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.
    Hing JP; Woolfrey SG; Greenslade D; Wright PM
    J Pharmacokinet Pharmacodyn; 2001 Oct; 28(5):465-79. PubMed ID: 11768291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.
    Xu XS; Dunne A; Kimko H; Nandy P; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2011 Aug; 38(4):423-32. PubMed ID: 21626437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of censoring data below an arbitrary quantification limit on structural model misspecification.
    Byon W; Fletcher CV; Brundage RC
    J Pharmacokinet Pharmacodyn; 2008 Feb; 35(1):101-16. PubMed ID: 17963024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.
    Nguyen TH; Comets E; Mentré F
    J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):499-518. PubMed ID: 22886041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation.
    Senn S; Holford N; Hockey H
    Stat Med; 2012 Dec; 31(30):4280-95. PubMed ID: 22825800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balanced designs in longitudinal population pharmacokinetic studies.
    Ette EI; Sun H; Ludden TM
    J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution.
    Yafune A; Takebe M; Ogata H
    J Pharmacokinet Biopharm; 1998 Feb; 26(1):103-23. PubMed ID: 9773395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.
    Keizer RJ; Jansen RS; Rosing H; Thijssen B; Beijnen JH; Schellens JH; Huitema AD
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00131. PubMed ID: 26038706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observations below multiple lower limits of quantification: How to estimate the mean and variance.
    Berger T; Hilgers RD; Heussen N
    Biom J; 2019 Sep; 61(5):1258-1269. PubMed ID: 30221408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of variability and uncertainty for censored data sets and application to air toxic emission factors.
    Zhao Y; Frey HC
    Risk Anal; 2004 Aug; 24(4):1019-34. PubMed ID: 15357825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.
    Duval V; Karlsson MO
    Pharm Res; 2002 Dec; 19(12):1835-40. PubMed ID: 12523662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of propofol in children using three different data analysis approaches.
    Kataria BK; Ved SA; Nicodemus HF; Hoy GR; Lea D; Dubois MY; Mandema JW; Shafer SL
    Anesthesiology; 1994 Jan; 80(1):104-22. PubMed ID: 8291699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A computer program for pharmacokinetics based on maximum likelihood estimation using the gamma distribution with a probability density function: comparison with the normal distribution.
    Tanikawa K; Matsumoto Y; Matsuzaki T; Shimizu M; Matsumoto M; Fukuoka M
    Biol Pharm Bull; 2000 Feb; 23(2):235-9. PubMed ID: 10706392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.